Who Paid My Doc
A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study
Research payments
$6,086,333
Through program year 2025, $6,086,333 in research payments was reported against A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study, across 242 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $71,392 | 2 |
| 2024 | Research | $7,752 | 9 |
| 2023 | Research | $340,684 | 26 |
| 2022 | Research | $1,126,668 | 88 |
| 2021 | Research | $4,539,837 | 117 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Moti Ramgopal Fort Lauderdale, FL Named on 27 payments
- Jeffrey Kingsley Columbus, GA Named on 27 payments
- Jaynier Moya Pembroke Pines, FL Named on 24 payments
- Jonathan Cohen Washington, DC Named on 13 payments
- Edwin Dejesus Orlando, FL Named on 11 payments
- Victor Escobar Jersey Village, TX Named on 10 payments
- Almena Free Anniston, AL Named on 9 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.